Vir Biotechnology, Inc. - News
Jan 8, 2025 · IR Contact. Vir Biotechnology, Inc. 1800 Owens St., Suite 900 San Francisco, CA 94158. contact us by phone 415-906-4324 info@vir.bio. Follow us. opens in a new window
Vir Biotechnology Catapults 58% On Promising Results In Cancer …
Jan 8, 2025 · Vir Biotechnology (VIR) announced promising results Wednesday for a pair of experimental cancer treatments. Vir stock catapulted by double digits. The company's drugs are T-cell engagers. These...
Vir Biotechnology, Inc. (VIR) Latest Stock News & Headlines
Get the latest Vir Biotechnology, Inc. (VIR) stock news and headlines to help you in your trading and investing decisions.
Vir Biotechnology, Inc. (VIR) Stock Price, News, Quote & History ...
Find the latest Vir Biotechnology, Inc. (VIR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Vir Biotechnology, Inc. - Vir Biotechnology Completes …
Mar 5, 2024 · SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier ...
Vir Biotechnology Announces Topline Data from Phase 2 …
Jul 20, 2023 · In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed.
Vir Biotechnology, Inc. - Vir Biotechnology Receives FDA IND …
SAN FRANCISCO-- (BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection.
Vir Lays Off 25% of Staff, Abandons Most Virus Work and ... - BioSpace
Aug 2, 2024 · As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.
Vir Biotechnology (NASDAQ:VIR) Shares Up 6.3% - What's Next?
3 days ago · Get Our Latest Report on Vir Biotechnology Vir Biotechnology Stock Up 6.4 %. Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal ; The stock has a market capitalization of $1.54 billion, a PE ratio of -2.86 and a beta of 0.51. The stock's 50-day moving average is $8.35 and its 200 day moving average is $8.44.
Vir Biotechnology, Inc. - Vir Biotechnology Acts on Expanded …
Aug 1, 2024 · SAN FRANCISCO-- (BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has entered into an exclusive worldwide license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases, acquired by Sanofi from Amu...